ENTA Enanta Pharmaceuticals, Inc.

12.37USD+1.64%Mkt Cap: 360.28M $P/E: —

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical …

Key Statistics

Company
Market Cap360.28M USD
Enterprise Value346.99M USD
Revenue (TTM)65.26M USD
Gross Profit65.26M USD
Net Income (TTM)-81.89M USD
Revenue/Share2.41 USD
Last Price12.37 USD
Fiscal Year EndSep 2025
MR QuarterJun 2026
Employees120
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.13
PEG—
EV/EBITDA-6.45
EV/Revenue5.32
P/S5.43
P/B3.51
EPS (TTM)-2.34
EPS (Forward)-2.37
52W Range
7.05053% of range17.15
52W High17.15 USD
52W Low7.050 USD
Profitability
Gross Margin100.00%
Oper. Margin-120.04%
EBITDA Margin-82.47%
Profit Margin-125.36%
ROE-126.53%
ROA-29.17%
Growth
Revenue Growth-21.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-19.27M USD
CapEx (TTM)12.90M USD
FCF Margin-34.72%
FCF Yield-6.29%
Net Debt-7.47M USD
Net Debt/EBITDA0.14
Balance Sheet
Debt/Equity0.89
Current Ratio3.76
Quick Ratio3.62
Book Value/Sh3.47 USD
Cash/Share6.51 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)21.83 USD
Upside (mean)+76.5%
Target Range19.00 USD – 32.00 USD
19.00+76.5% to mean32.00
# Analysts6
Ownership
Shares Out.29.13M
Float22.52M
Insiders4.67%
Institutions94.39%
Short Interest
Short Ratio10.2d
Short % Float10.68%
Short % Out.8.93%
Shares Short2.60M
Short (prev mo.)2.68M
Technical
SMA 5013.10 (-5.6%)
SMA 20013.48 (-8.3%)
Beta0.96
S&P 52W Chg16.45%
Avg Vol (30d)272.66K
Avg Vol (10d)319.08K
Technical Indicators
RSI (14)44.9
MACD-0.1922
MACD Signal-0.2070
MACD Hist.+0.0148
BB Upper13.53 USD
BB Middle12.59 USD
BB Lower11.64 USD
BB Width14.97%
ATR (14)0.5809 USD
Vol Ratio (20d)0.66x